Health Care

GE Healthcare expands its $35 M BARDA partnership to develop AI‑enabled ultrasound, speeding trauma diagnostics, cutting costs and easing operator demands.

Read how Bayer’s $7.25 billion Roundup settlement and U.S. special status shift investor sentiment, legal risk, and future product pricing.

Danaher’s $9.5 B purchase of Masimo promises diagnostics growth, RPM access and $300 M revenue synergies, but integration, FDA delays and supply‑chain risks loom.

Recordati’s 2025 results show 6% revenue growth and 15% EBITDA lift, driven by Specialty & Primary Care and a breakthrough Rare Diseases therapy, positioning the firm for 2027 gains.

Labcorp’s Q4 2026 earnings show steady growth, AI‑powered specialty testing and a strong outlook, positioning the diagnostics leader for future value‑based care expansion.

Qiagen’s strategic position amid the Danaher‑Masimo deal shows how diagnostics firms can thrive by leveraging regulatory strengths and exploring cross‑sector partnerships to stay competitive in a consolidating market.

EssilorLuxottica’s modest share rise on Feb 16, 2026, signals strong market confidence, while its own‑share transaction hints at value creation amid expected European easing.

Regeneron’s biopharma strategy focuses on high‑growth cardiovascular, ocular, and niche biologics, balancing R&D costs, value‑based pricing, and competitive pressures for long‑term revenue gains.

Sanofi’s Phase 2b duvakitug data boost IBD prospects, a Hyderabad GCC expansion cuts costs, and new RSV vaccine Beyfortus targets a $2.8 billion market. Click to see how these moves could generate $1.1 billion annual revenue.

IQVIA’s AI strategy faces scrutiny as TD Cowen cuts its target, while a partnership with Isdin could unlock consumer‑health growth – can the company monetize AI amid regulatory pressure?